Latest Kidney Cancer News
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Kidney cancer and some other cancers tied to obesity are increasing the most rapidly among individuals younger than 50.
First-line treatment of metastatic renal cell carcinoma with tyrosine kinase inhibitors is associated with worse progression-free and overall survival in patients with non-clear-cell vs clear-cell histology.
Routine partial nephrectomy yielded longest life expectancy in patients with normal renal function.
A history of kidney stones is associated with an increased risk of papillary renal cell carcinoma and upper tract urothelial carcinoma, according to a large prospective study.
In a small study, sunitinib recipients who took royal jelly, a substance produced by worker honeybees for queen bees, were less likely to experience fatigue and anorexia than those who took placebo.
Researchers theorize that KPNA2 expression could be used in the future to stratify risk groups among patients with renal cell carcinoma (RCC).
A review article examines the challenges in pathologic staging and grade reporting for patients with renal cell carcinoma.
Lymph node dissection did not influence overall survival even among patients with clinically positive nodal disease.
Avelumab plus axitinib is associated with longer progression-free survival compared with sunitinib as first-line therapy in patients with advanced renal cell carcinoma.
Renal and Urology News Articles
- Study Supports Once-Daily Plazomicin Use for Complicated UTIs
- Prednisone to Blame for ERA 223 Trial Failure?
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)